Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a prospective single-arm phase II study, and the purpose of this study is to evaluate
the efficiency of ZR regimen (rituximab & Zanubrutinib) combined with intravitreal
methotrexate and followed by Zanubrutinib maintenance in newly-diagnosed primary intraocular
lymphoma. Progression-free survival (PFS) of the cohort is the primary endpoint.